血清孕酮、IL-8、TNF-α在先兆流产中的意义

目的:探讨血清孕酮、IL-8和TNF-α在判断先兆流产预后中的价值。方法:①选择101例患者,分为先兆流产组(47例)、难免流产组(21例)和正常早孕组(33例)。均抽取静脉血检查血清孕酮、IL-8和TNF-α。②根据治疗结果将先兆流产患者分为成功组和失败组,运用受试者工作特性曲线(ROC曲线),确定用以预测治疗成功与否的血清孕酮临界值。结果:①3组患者的血清孕酮、IL-8、TNF-α水平差异有显著性(P<0.01)。②运用ROC曲线,我们推荐血清孕酮39.6 nmol/L作为预测先兆流产治疗成功与否的临界值。③IL-8和TNF-α随病情的好转而降低。结论:①血清孕酮、IL-8和TNF-α可以作为判断先兆流产预后的参考指标。②IL-8和TNF-α可能参与了先兆流产的发生发展。     

大鼠NSCs向多巴胺能神经元分化研究

目的：探讨IL-1β对神经干细胞（NSCs）分化为多巴胺能神经元作用：方法：体外培养和鉴定中脑来源NSCs，用免疫学方法检测分化细胞酪氨酸羟化酶（TH）表达.结果：血清组、IL-1β10pg／ml组、IL-1β120pg／ml组、IL-1β150pg／ml组、IL-1β200pg／ml组诱导7d后TH细胞分别平均为0,45％、0．6％、7.2％、12．5％、8．75％：结果显示IL-1β诱导NSCs明显提高TH细胞表达率，与血清组比较有显著性差异（P〈0，05），在IL-1β150pg／ml剂量范同内TH细胞表达率与剂量呈正相关。结论：IL-1β有诱导NSC向多巴胺能神经元分化的显著作用：     

以羊水中粒细胞集落刺激因子预测绒毛膜羊膜炎的价值

目的：通过检测分娩时羊水中GCSF和IL-6的含量及其与病理诊断为绒毛膜羊膜炎（CAM）的关系，研究测定羊水中G-CSF和IL-6的含量用以预测CAM的价值。方法：将研究对象按是否胎膜早破分为两组，均排除产科并发症及内外科合并症。两组产妇于分娩时抽取羊水5ml,用ELISA法检测羊水中G-CSF和IL-6的含量，同时两组产妇均于产后留取胎膜，用HE染色法检测是否存在CAM。结果：胎膜早破（PROM）组与对照组在年龄、孕周间差异无显著性的条件下，PROM组羊水中G-CSF和IL-6的含量高于对照组，差异有显著性，并且随着破膜时间延长而增高，各组间差异有显著性；CAM组羊水中G-CSF和IL-6的含量高于非CAM组，并且随着病理级别的增加，羊水中G-CSF和IL-6的的含量增加，其水平高低和胎盘炎症的组织学分级有明显的线性关系，组间差异有显著性；G-CSF与IL-6相比有较高的敏感性和特异性。结论：羊水中C-CSF、IL-6可作为CAM的早期诊断指标，且G-CSF优于IL-6。羊水中G-CSF、IL-6可作为反映绒毛膜羊膜炎严重程度的指标。     

清热抗感冲剂对小鼠IL-2水平影响的实验研究

目的:通过检测清热抗感冲剂对实验性免疫低下小鼠及正常小鼠血清IL-2水平的影响,探讨该冲剂对免疫功能的调节作用.方法:选取昆明种小鼠100只,雌雄各半,其中50只腹腔注射环磷酰胺3mg/0.2mL/只,每天给药1次,连续7天,造成免疫低下小鼠,然后随机分为模型组、中药对照组(银翘解毒片组)、西药对照组(γ-干扰素组)、小剂量组、大剂量组;其余50只随机分为正常空白对照组(即生理盐水组)、中药对照组、西药对照组、小剂量组、大剂量组.上述各组连续用药3天后,处死,采血,离心取血清,采用放免γ测量仪检测IL-2含量.结果:清热抗感冲剂能显著提高正常小鼠和注射环磷酰胺引起的免疫低下小鼠血清中IL-2生成水平(统计学处理P＜0.01).结论:清热抗感冲剂对小鼠的细胞免疫功能有明显的增强作用.     

茶叶多糖对小鼠激发态免疫功能影响的研究

目的:探讨茶叶多糖对小鼠免疫反应的影响及作用机理.方法:分别用羊红细胞和卵清蛋白为抗原给小鼠注射后,灌服茶叶多糖并设置对照组,检测相应抗体生成水平和血清中IL-2、IFN-γ生成水平.结果:给药组SRBC抗体生成水平和卵清抗体生成水平,IL-2、IFN-γ激发水平均显著高于对照组(P＜0.05).结论:提示茶叶多糖对正常小鼠机体免疫有增强作用.     

Association between interleukin-10 genetic polymorphisms and risk of primary open angle glaucoma in a Chinese Han population: a case-control study

AIM: To investigate the association between interleukin-10 (IL-10) genetic polymorphisms and risk of POAG through a case-control study in a Han population of China. METHODS: A total of 210 patients with POAG and 420 normal subjects were recruited during the period from Dec. 2013 to Dec. 2016. The IL-10 -1082A>G (rs1800870), -819T>C (rs1800871) and -592C>A (rs1800872) polymorphisms were determined using iPlex GOLD SNP genotyping analysis (the SequenomMassARRAY® System, Sequenom, San Diego, USA). The association between IL-10 -1082A>G (rs1800870), -819T>C (rs1800871), and -592C>A (rs1800872) polymorphisms and risk of POAG was assessed by singlelogistic regression analysis. RESULTS: We observed that those carrying the CC genotype of rs1800871 was associated with an increased risk of POAG when compared with those harboring the TT genotype (OR=1.84, 95%CI=1.01-3.38). Those with AA genotype of rs1800872 had a 10.62 fold risk of POAG in comparison to the CC genotype (OR=10.62, 95%CI, 3.41-33.09). A completely linkage disequilibrium was found between IL-10 rs1800871-rs1800872 (D’=1.00, r2=0.16). The A-C-A (OR=2.60, 95%CI, 1.48-4.58) and G-T-A (OR=2.34, 95%CI, 1.42-3.86) haplotypes were associated with an increased risk of POAG, while the A-T-C haplotype showed a decreased risk of POAG (OR=0.63, 95%CI, 0.49-0.81). CONCLUSION: Our data suggest that IL-10 rs1800871 and rs1800872 can be predictive factors for the pathogenesis of POAG in the Chinese population.     

Effectiveness,nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients

ObjectivesWe aimed to assess the effectiveness and nephrotoxicity of polymyxin B in critically ill patients with nosocomial pneumonia and to evaluate the utility of its therapeutic drug monitoring (TDM).MethodsWe retrospectively analyzed patients who received polymyxin B treatment for ≥48 h since the establishment of polymyxin B TDM in a 26‐bed tertiary referral intensive care unit. Univariate and multivariate analyses were conducted to assess the variables associated with polymyxin B effectiveness and nephrotoxicity.ResultsA total of 62 patients were enrolled. Most (56.5%) of the patients performed TDM, 54.3% of them reached the therapeutic target of area under curve across 24 h at steady state (AUC_ss,24h) of 50–100 mg h L⁻¹, and 10 patients had an AUC_ss,24h value of <50 mg h L⁻¹. Thirty‐six (58.1) and 31 (50.0%) patients had favorable clinical and microbiological responses, respectively. Reaching the therapeutic target of AUC_ss,24h (odds ratio [OR] = 13.15, p = 0.015), a favorable microbiological response (OR = 40.80, p = 0.00), and complicated with septic shock (OR = 0.12, p = 0.021) were independently associated with favorable clinical outcomes of polymyxin B treatment. The incidence of acute kidney injury (AKI) was 45.2%. A lower creatinine clearance (OR = 0.96, p = 0.008) and concomitant treatment with loop diuretics (OR = 5.93, p = 0.046) were predictive of nephrotoxicity.ConclusionOur findings show that TDM of polymyxin B is a valuable intervention, and the achievement of its optimal pharmacodynamic target can improve treatment outcome. Renal insufficiency and concomitant treatment with loop diuretics were found to be associated with the risk of nephrotoxicity.     

杜仲苷对炎性环境下软骨细胞的增殖和Ⅱ型胶原蛋白分泌的影响

目的：观察杜仲苷对IL-1β刺激大鼠体外软骨细胞的增殖及Ⅱ型胶原蛋白分泌的影响。方法：利用IL-1β刺激建立体外大鼠软骨细胞炎性模型,实验分为空白组、IL-1β组、10μM杜仲苷组、100μM杜仲苷组、500μM杜仲苷组、1000μM杜仲苷组;空白组加入10%FBS培养液,IL-1β组加入10ng/mL IL-1β＋10%FBS培养液,4个不同浓度杜仲苷组分别加入10μM、100μM、500μM、1000μM杜仲苷＋10ng/mL IL-1β＋10%FBS培养液,分别培养48小时,采用CCK8检测软骨细胞增殖活力及Ⅱ型胶原蛋白的分泌。结果：IL-1β组的OD值低于空白组（P〈0.05）;4个不同浓度杜仲苷组的OD值均高于IL-1β组（P〈0.05）,且存在一定的量效关系;4个不同浓度杜仲苷组的Ⅱ型胶原蛋白表达均高于IL-1β组（P〈0.05）,且存在有一定的量效关系。结论：杜仲苷可以提高体外大鼠软骨细胞炎性环境下的增殖活力,促进Ⅱ型胶原蛋白的分泌,表明杜仲苷对体外大鼠软骨细胞有一定的抗炎保护作用。     

A 24-hour rhythm in passive-avoidance behaviour in rats

The 24 h variation in the passive avoidance response of rats was measured. Different groups of 18 animals were tested at 4 hourly intervals throughout 24 h. In all cases, retention was measured 48 h after the first trial. All animals were housed under controlled conditions for 14 days before testing. A significant 24-h rhythm in passive avoidance response was found, the maximum and minimum effects being in the middle of the light and dark phases respectively.     

萆薢分清丸联合头孢唑肟钠治疗尿路感染的临床研究

目的探讨萆薢分清丸联合头孢唑肟钠治疗尿路感染的临床疗效。方法选取2015年11月—2017年1月在上海市宝山区中西医结合医院进行治疗的尿路感染患者200例,随机分为对照组(100例)和治疗组(100例)。对照组患者静脉滴注注射用头孢唑肟钠,2 g/次,2次/d。治疗组在对照组的基础上口服萆薢分清丸,6 g/次,2次/d。两组患者均连续治疗7 d。观察两组患者临床效果,比较两组患者治疗前后临床症状改善时间和血清细胞因子水平。结果治疗后,对照组和治疗组临床有效率分别为83.00%和97.00%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患者尿频、尿急和尿痛改善时间比对照组显著缩短,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血清降钙素原(PCT)、C反应蛋白(CRP)和白细胞介素-6(IL-6)水平均显著降低,同组比较差异具有统计学意义(P0.05);且治疗组患者的细胞因子水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论萆薢分清丸联合头孢唑肟钠可有效改善尿路感染患者临床症状,降低机体PCT水平,具有一定的临床推广应用价值。